Validation of a Japanese version of RECAP questionnaire for adult patients with atopic dermatitis and parents of pediatric patients

Validation of a Japanese version of RECAP questionnaire for adult patients with atopic dermatitis and parents of pediatric patients - A prospective validation study of the Japanese version of RECAP questionnaire

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047132

Enrollment

200

Registered

2022-03-10

Start date

2023-01-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet the diagnostic criteria for atopic dermatitis and are currently on guideline-directed treatment are eligible.

Exclusion criteria

Exclusion criteria: Patients on biologic agents or oral JAK inhibitors with a vIGA score of 0 or 1 at the time of enrollment Patients with serious complications Patients receiving oral or intravenous immunosuppressive drugs (except cyclosporine and JAK inhibitors) and steroids If the patient is considered to have difficulty in answering the questionnaire. When the principal investigator or sub-investigator judges that participation in this study is not appropriate.

Design outcomes

Primary

Measure	Time frame
Correlation coefficient between RECAP and each score (EASI, vIGA, ADCT, POEM, IDQoL, CDLQI, DLQI, DFI, NRS)	—

Secondary

Measure	Time frame
Cronbach's alpha coefficient for each RECAP score, Intraclass correlation coefficient between test and retest in patients with no change in EASI and vIGA, Means and 95% confidence intervals of RECAP total scores among subgroups divided by vIGA scores, Means and 95% confidence intervals for differences from adjacent groups divided by vIGA scores, Minimum clinically meaningful change (MCID), Correlation coefficient with TARC and SCCA2, Correlation coefficients between changes in RECAP and changes in each score, and Area under the ROC curve of RECAP and ADCT for a rise in vIGA from 0 or 1 to >2 (relapse)	—

Measure

Time frame

Cronbach's alpha coefficient for each RECAP score, Intraclass correlation coefficient between test and retest in patients with no change in EASI and vIGA, Means and 95% confidence intervals of RECAP total scores among subgroups divided by vIGA scores, Means and 95% confidence intervals for differences from adjacent groups divided by vIGA scores, Minimum clinically meaningful change (MCID), Correlation coefficient with TARC and SCCA2, Correlation coefficients between changes in RECAP and changes in each score, and Area under the ROC curve of RECAP and ADCT for a rise in vIGA from 0 or 1 to >2 (relapse)

—

Countries

Japan

Contacts

Public ContactTakaaki Itonaga

National Hospital Organization Sagamihara National Hospital Department of pediatrics

sagamihara.ad@gmail.com042-742-8311

Outcome results